Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Phase II Trial Evaluating The Efficacy Of A Multiepitope Dendritic Cell Vaccine Given With Trastuzumab And Vinorelbine For The Treatment Of Women With Metastatic Breast Cancer That Express HLA-A0201
Sponsor: National Cancer Institute (NCI)
Listed as NCT00088985, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 10 times since 2004, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Susan G. Komen Breast Cancer Foundation
- UNC Lineberger Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Chapel Hill, United States